• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

    4/15/25 6:30:00 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SAGE alert in real time by email

    Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that it will host a live webcast on Tuesday, April 29, 2025, at 4:30 p.m. ET to review first quarter 2025 financial results and discuss recent business updates.

    The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

    About Sage Therapeutics

    Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at www.sagerx.com or engage with us on Facebook, LinkedIn, Instagram, and X.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250414189773/en/

    Investor Contact

    Ashley Kaplowitz

    [email protected]

    Media Contact

    Francesca Dellelci

    [email protected]

    Get the next $SAGE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SAGE

    DatePrice TargetRatingAnalyst
    3/11/2025$5.00Underperform
    BofA Securities
    11/21/2024$4.00Underperform → Sector Perform
    RBC Capital Mkts
    10/10/2024Mkt Perform
    Raymond James
    10/4/2024$10.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    7/30/2024$16.00 → $10.00Buy → Hold
    TD Cowen
    7/25/2024$18.00 → $12.00Overweight → Neutral
    JP Morgan
    5/29/2024$15.00Neutral
    Robert W. Baird
    5/29/2024$8.00Sell
    Citigroup
    More analyst ratings

    $SAGE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 4, 2023 - La FDA aprueba el primer tratamiento oral para la depresión posparto

    For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas

    8/8/23 9:34:19 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 4, 2023 - FDA Approves First Oral Treatment for Postpartum Depression

    For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health

    8/4/23 6:50:31 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities resumed coverage on SAGE Therapeutics with a new price target

    BofA Securities resumed coverage of SAGE Therapeutics with a rating of Underperform and set a new price target of $5.00

    3/11/25 7:43:31 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SAGE Therapeutics upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded SAGE Therapeutics from Underperform to Sector Perform and set a new price target of $4.00

    11/21/24 7:42:56 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on SAGE Therapeutics

    Raymond James resumed coverage of SAGE Therapeutics with a rating of Mkt Perform

    10/10/24 8:30:27 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Quirk Michael C. returned 32,961 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

    7/31/25 12:04:37 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Federer Jessica

    4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

    7/31/25 12:03:01 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Benecchi Christopher returned 64,428 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

    7/31/25 11:57:08 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    SEC Filings

    View All

    SEC Form 15-12G filed by Sage Therapeutics Inc.

    15-12G - Sage Therapeutics, Inc. (0001597553) (Filer)

    8/11/25 5:00:17 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POSASR filed by Sage Therapeutics Inc.

    POSASR - Sage Therapeutics, Inc. (0001597553) (Filer)

    8/1/25 5:22:10 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POSASR filed by Sage Therapeutics Inc.

    POSASR - Sage Therapeutics, Inc. (0001597553) (Filer)

    8/1/25 5:21:50 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

    ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ("Supernus") today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. (NASDAQ:SAGE) ("Sage"). "Sage is an ideal fit in our corporate development strategy, adding a significant fourth growth product to our portfolio and further diversifying our sources of future revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "With our proven track record of strong commercial execution along with the expected cost synergies, the acquisition is expected to be accretive in 2026." Compelling Strategic Rationale Strengthens psychi

    7/31/25 8:44:03 AM ET
    $SAGE
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sage Therapeutics Announces Second Quarter 2025 Financial Results

    Achieved $23.2 million in ZURZUVAE® (zuranolone) collaboration revenue in the second quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 68% increase from the first quarter Previously announced acquisition by Supernus Pharmaceuticals expected to close in third quarter of 2025 Cash, cash equivalents, and marketable securities of $366 million as of June 30, 2025 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025. "Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our c

    7/30/25 4:05:00 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

    ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ:SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), with respect to Supernus' proposed acquisition of Sage Therapeutics, Inc., a Delaware corporation (NASDAQ:SAGE) ("Sage"), expired at 11:59 p.m. Eastern Time on July 25, 2025. On June 13, 2025, Supernus and Sage, entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among Supernus, Sage and Saphire, Inc., a Delaware corporation and a wholly owned subsidiary of Supernus ("Purchaser")

    7/28/25 8:25:15 AM ET
    $SAGE
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    Financials

    Live finance-specific insights

    View All

    Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

    ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ("Supernus") today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. (NASDAQ:SAGE) ("Sage"). "Sage is an ideal fit in our corporate development strategy, adding a significant fourth growth product to our portfolio and further diversifying our sources of future revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "With our proven track record of strong commercial execution along with the expected cost synergies, the acquisition is expected to be accretive in 2026." Compelling Strategic Rationale Strengthens psychi

    7/31/25 8:44:03 AM ET
    $SAGE
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sage Therapeutics Announces Second Quarter 2025 Financial Results

    Achieved $23.2 million in ZURZUVAE® (zuranolone) collaboration revenue in the second quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 68% increase from the first quarter Previously announced acquisition by Supernus Pharmaceuticals expected to close in third quarter of 2025 Cash, cash equivalents, and marketable securities of $366 million as of June 30, 2025 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025. "Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our c

    7/30/25 4:05:00 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

    Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share.Supernus to host confe

    6/16/25 7:00:06 AM ET
    $SAGE
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    Leadership Updates

    Live Leadership Updates

    View All

    Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

    FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Ms. Cook is an accomplished pharmaceutical legal executive with a proven track record advising pharmaceutical companies and broad expertise in corporate governance, commercial law, regulatory compliance, strategic transactions and legal strategy. Ms. Cook most recently served as Senior Vice President, General Counsel of Sage Therapeutics, Inc. and previously se

    6/23/25 7:59:57 AM ET
    $PHAT
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sage Therapeutics Announces R&D Leadership Transition

    Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company's product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis. "I would like to extend my sincerest gratitude to Laura for her leadership and dedication to advancing innovation for patients with debilitating brain health conditions," said Barry Greene, Chief Executive Officer of

    3/4/25 4:15:00 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sage Therapeutics Appoints Jessica Federer to Board of Directors

    Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230316005117/en/Jessica Federer (Photo: Business Wire) "We are thrilled to have Jessica join our Board of Directors. Jessica is a champion for patients and has a track record of innovation in data and digital transformation which will be a key future growth driver for the industry," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "Jessica's innate curiosit

    3/16/23 6:30:00 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/14/24 6:14:58 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/12/24 4:56:16 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/12/24 10:34:18 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care